334
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Effect of preparation techniques on the properties of curcumin liposomes: Characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line

&
Pages 103-109 | Received 22 Apr 2010, Accepted 26 Aug 2010, Published online: 24 Nov 2010

References

  • Love RR, Leventhal H, Easterling DV, Nerenz DR. Side-effects and emotional distress during cancer chemotherapy. Cancer 1989;63(3):604–612.
  • Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007;595:105–125.
  • Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin. Adv Exp Med Biol 2007;595:149–172.
  • Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 2003:23(1A):363–398.
  • Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, Reddy BS. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999;59(3):597–601.
  • Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995;55(2):259–266.
  • Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006;6(3):259–270.
  • Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat Res 2006;596(1–2):81–90.
  • Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10(20):6847–6854.
  • Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2. Mol Cancer Ther 2004;3(9):1101–1108.
  • Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4(6):807–818.
  • Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11(1):105–111.
  • Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471–480.
  • Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007;853(1–2):183–189.
  • Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004;90(5):1011–1015.
  • Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC. Complement Altern Med 2006;6:10.
  • Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res 2001;7(7):1894–1900.
  • Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, WangYJ Tsai, CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21(4B):2895–2900.
  • Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271(1):58–65.
  • Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007;9(2):E128–147.
  • Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007;60(2):171–177.
  • Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. Polymeric nanoparticle-encapsulated curcumin (‘nanocurcumin’): A novel strategy for human cancer therapy. J Nanobiotechnol 2007:5:3.
  • Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104(6):1322–1331.
  • Chen H-C, Thomas JL, Lee M.-H, Lin H-Y. Control of the release of curcumin from micelles by ultrasound. Proceedings of the IEEE 31st Annual Northeast 2005;2:271–272.
  • Chen H-C Lin, H-Y, Lin C-C Lee, M-H. The encapsulation of curcumin in micelles. Proceedings of the IEEE 31st Annual Northeast 2005;2:275–276.
  • Fan M, Xu S, Xia S, Zhang X. Effect of different preparation methods on physicochemical properties of salidroside liposomes. J Agric Food Chem 2007;55(8):3089–3095.
  • Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int J Pharm 2004;285(1–2):23–34.
  • Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979;557(1):9–23.
  • Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M, Carminati P, Luisi PL. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res 2004;14(1–2):87–109.
  • Began G, Sudharshan E, Sankar KU, Rao AG. Interaction of curcumin with phosphatidylcholine: A spectrofluorometric study. J Agric Food Chem 2000;48(2):576.
  • Frantzen CB, Ingebrigtsen L, Skar M, Brandl M. Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions. AAPS. PharmSciTech 2003;4(3):E36.
  • Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15(7–8):457–464.
  • Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11(17–18):812–818.
  • Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006;8(1):39–45.
  • Nounou MM, El-Khordagui LK, Khalafallah N. Release stability of 5-fluorouracil liposomal concentrates, gels and lyophilized powder. Acta Pol Pharm 2005;62(5):381–391.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.